Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines
1996

Aclarubicin's Effectiveness Against Drug-Resistant Liver Cancer Cells

publication Evidence: moderate

Author Information

Author(s): G Lehne, P De Angelis, OPF Clausen, HE Rugstad

Primary Institution: The National Hospital, Rikshospitalet, Oslo, Norway

Hypothesis

Can aclarubicin retain its effectiveness in human hepatoma cells that overexpress P-glycoprotein?

Conclusion

Aclarubicin remains effective in multidrug-resistant human hepatoma cells, unlike other anthracyclines.

Supporting Evidence

  • Aclarubicin was effective in inhibiting cell growth in resistant hepatoma cells.
  • Other anthracyclines showed high resistance in the same cell line.
  • SDZ PSC 833 enhanced the effectiveness of other anthracyclines but not aclarubicin.

Takeaway

Aclarubicin is a special medicine that can still work against certain cancer cells that usually resist treatment.

Methodology

The study compared the effects of four anthracyclines on human hepatoma cell lines with different levels of P-glycoprotein.

Limitations

The study was conducted in vitro, and results may not fully translate to clinical settings.

Statistical Information

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication